This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erkkilä, L.
Right arrow Articles by Leinonen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erkkilä, L.
Right arrow Articles by Leinonen, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3959-3962, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3959-3962.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice

Leena Erkkilä,1* Matti Jauhiainen,2 Kirsi Laitinen,3 Kristiina Haasio,4 Terttu Tiirola,2 Pekka Saikku,1,5 and Maija Leinonen1

National Public Health Institute, Department of Viral Diseases and Immunology, Oulu, Finland,1 National Public Health Institute, Department of Molecular Medicine, Helsinki, Finland,2 Department of Public Health, University of Helsinki, Helsinki, Finland,3 Orion Pharma, Espoo, Finland,4 Department of Medical Microbiology, University of Oulu, Oulu, Finland5

Received 11 October 2004/ Returned for modification 8 February 2004/ Accepted 1 July 2005

The effects of simvastatin treatment on Chlamydia pneumoniae lung infection, inflammation, and serum lipids in mouse model were studied. Simvastatin decreased viable chlamydial counts and increased inflammatory cell infiltrates in the lung tissue, suggesting that simvastatin treatment had both antichlamydial and immunomodulatory effects during an acute C. pneumoniae infection.

* Corresponding author. Mailing address: National Public Health Institute, Department of Viral Diseases and Immunology, P.O. Box 310, 90101 Oulu, Finland. Phone: 358 8 5376219. Fax: 358 8 5376251. E-mail: leena.erkkila{at}ktl.fi

Antimicrobial Agents and Chemotherapy, September 2005, p. 3959-3962, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3959-3962.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Siempos, I. I., Vardakas, K. Z., Kopterides, P., Falagas, M. E. (2008). Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 62: 661-668 [Abstract] [Full Text]  
  • Mira, E., Leon, B., Barber, D. F., Jimenez-Baranda, S., Goya, I., Almonacid, L., Marquez, G., Zaballos, A., Martinez-A., C., Stein, J. V., Ardavin, C., Manes, S. (2008). Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway. J. Immunol. 181: 3524-3534 [Abstract] [Full Text]  
  • Merx, M.W., Weber, C. (2007). Sepsis and the Heart. Circulation 116: 793-802 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»